Thesis defence in the University of Oulu

Doctoral Candidate

Licentiate of Medicine Reetta Arima

Faculty and research unit

University of Oulu Graduate School, Faculty of Medicine, PEDEGO

Field of study


Date and time of the thesis defence

11.10.2019 12:00

Place of the thesis defence

Auditorium 4 of Oulu University Hospital

Topic of the dissertation

Metformin, statins and the risk and prognosis of endometrial cancer in women with type 2 diabetes


Docent Sakari Hietanen, Turku University Hospital/University of Turku


Professor Ulla Puistola, Oulu University Hospital/University of Oulu

Use of statins associated with lower risk of endometrial cancer in women with type 2 diabetes

A dissertation research explored whether the use of antidiabetic medication metformin or cholesterol-lowering statins affects the risk or prognosis of endometrial cancer in women with type 2 diabetes.

Endometrial cancer is the fifth most common female cancer worldwide. The prognosis of endometrial cancer is fairly good but gets worse in the widespread or relapsed cases.

Metformin, that is commonly used to treat type 2 diabetes and statins have prevented the growth of endometrial cancer cells in earlier studies performed in laboratories. Studies including patients using metformin or statins have had varying results.

In the dissertation research, which is based on a nationwide diabetes database, the use of metformin was not associated with the risk or prognosis of endometrial cancer. However, in statin users the risk of endometrial cancer and mortality from non-endometrioid subtype was lower.

In the future it would be interesting to study the effect of statins on the prognosis of endometrial cancer as a part of the medical treatment of patients.



Last updated: 4.10.2019